A new study from Northwestern Medicine suggests that current lung cancer screening guidelines may be missing most Americans who develop the disease — and researchers say it’s time for a major change.

Published in JAMA Network Open, the study analyzed nearly 1,000 lung cancer patients who were treated at Northwestern Medicine between 2018 and 2023. 

The goal was to see how many of those patients would have qualified for screening under existing guidance from the U.S. Preventive Services Task Force (USPSTF).

STEALTH BREAST CANCER THAT HIDES FROM SCANS TARGETED IN BREAKTHROUGH TECH

USPSTF currently recommends annual CT scans for adults ages 50 to 80 who have a 20 pack-year smoking history (the equivalent of one pack of cigarettes per day for 20 years) and either still smoke or quit within the last 15 years.

Only about 35% of those diagnosed with lung cancer met the current criteria to undergo screenings.

That means roughly two-thirds of patients would not have been flagged for testing before their diagnosis.

“Not only does that approach miss many patients who had quit smoking in the past or did not quite meet the high-risk criteria, it also misses other patients at risk of lung cancer, such as non-smokers,” Luis Herrera, M.D., a thoracic surgeon at Orlando Health, told Fox News Digital.

The study noted that these patients tended to have adenocarcinoma, the most common type of lung cancer among never-smokers.

Those missed by the guidelines were more often women, people of Asian descent and individuals who had never smoked, the study found.

The research team also compared survival outcomes. Patients who didn’t meet the screening criteria had better survival, living a median of 9.5 years compared with 4.4 years for those who did qualify. 

ERIN ANDREWS HAD ‘NO SYMPTOMS’ BEFORE CANCER DIAGNOSIS, PUSHES FOR EARLY SCREENINGS

While this difference partly reflects tumor biology and earlier detection, it also highlights how current screening rules fail to catch a broad range of cases that could be treated sooner, according to researchers.

“The current participation in lung cancer screening for patients who do qualify based on smoking history is quite low,” said Herrera, who was not involved in the study. This is likely due to the complexity of the risk-based criteria and stigma associated with smoking and lung cancer, he added.

CLICK HERE FOR MORE HEALTH STORIES

To test an alternative, the researchers modeled a different approach: screening everyone between the ages of 40 and 85, regardless of smoking history. 

Under that universal, age-based model, about 94% of the cancers in their cohort would have been detected.

Such a change could prevent roughly 26,000 U.S. deaths each year, at a cost of about $101,000 per life saved, according to their estimates. 

The study emphasized that this would be far more cost-effective than current screening programs for breast or colorectal cancer, which cost between $890,000 and $920,000 per life saved.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Herrera noted the many challenges in the adoption of lung cancer screening, from lack of awareness to some providers not recommending the screening test.

However, he added, “The cost of screening is covered by most health insurance plans and many institutions also offer discounts for patients who don’t have insurance.”

“The current participation in lung cancer screening for patients who do qualify based on smoking history is quite low.”

Lung cancer remains the deadliest cancer in the country, killing more people each year than colon, prostate and breast cancer combined. But because of the narrow eligibility criteria based on smoking history, millions at risk never get screened.

Northwestern Medicine researchers argue that expanding screening to include all adults within an age range could help close those gaps, especially for groups often underdiagnosed.

The study was conducted at a single academic center, which means the patient population may not represent the wider U.S. population. It also looked back at existing data, so it can’t prove how the new model would perform in real-world screening programs, the researchers acknowledged.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The cost and mortality projections rely on assumptions that could shift depending on how screening is implemented. 

The researchers also didn’t fully account for the potential downsides of broader screening, such as false positives or unnecessary follow-ups, they noted.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

For patients who don’t qualify for lung cancer screening, there are other opportunities for lung evaluations, including “heart calcium scores, CT scans and other imaging modalities that can at least evaluate the lungs for any suspicious nodules,” Herrera added.

Days after Tatiana Schlossberg announced that she has terminal cancer, the spotlight is on the warning signs of acute myeloid leukemia (AML).

John F. Kennedy’s granddaughter, 35, shared the details of her diagnosis in an essay published in The New Yorker on Nov. 22.

Schlossberg, who is the daughter of Kennedy’s daughter, Caroline Kennedy, and Edwin Schlossberg, learned of her disease in May 2024. 

KATE MIDDLETON SHARES PHOTO TAKEN BY PRINCE LOUIS WITH POIGNANT MESSAGE AFTER CANCER BATTLE

She wrote that one doctor predicted she would live for about a year.

The first indicator of Schlossberg’s disease was an abnormally high white blood cell count, which doctors detected just hours after she gave birth to her second child.

What is acute myeloid leukemia?

AML is a type of leukemia that begins in the bone marrow, the soft, inner tissue of certain bones where new blood cells are produced, according to the American Cancer Society.

This type of cancer typically spreads rapidly from the bone marrow into the bloodstream and can also reach other parts of the body, such as the lymph nodes, liver, spleen, brain and spinal cord, and testicles, per ACS.

EXPERIMENTAL VACCINE FOR COMMON CANCER SHOWS POTENTIAL IN CLINICAL TRIAL

In some cases, clusters of leukemia cells may form a solid mass known as a myeloid sarcoma.

Schlossberg’s AML stems from a rare gene mutation known as inversion 3, which is an abnormality of chromosome 3 in the leukemia cells.

“Inversion 3 correlates with a very high rate of resistance to standard chemotherapy treatments and, therefore, very poor clinical outcomes,” Dr. Stephen Chung, a leukemia expert and oncologist at UT Southwestern Medical Center in Dallas, Texas, told Fox News Digital. (Chung was not involved in Schlossberg’s care.)

Red flags and risk factors

The most common symptoms of Schlossberg’s type of cancer include sudden onset of severe fatigue, shortness of breath with exertion, unusual bleeding or bruising, fever and infections, according to Dr. Pamela Becker, professor in the Division of Leukemia at City of Hope, a U.S. cancer research and treatment organization in California, who also did not treat Schlossberg.

AML can sometimes resemble a severe flu with a generally unwell feeling. 

Chung noted that AML usually causes abnormally low blood cell counts, or in some cases an abnormally high white blood cell count.

4 TROUBLING CANCER TRENDS YOU MUST KNOW ABOUT IN 2025

“This may be picked up in routine testing for other purposes, or because the patient develops symptoms from these low blood counts,” he said. 

AML can sometimes resemble a severe flu with a generally unwell feeling, noted Robert Sikorski, M.D., Ph.D., a hematology/oncology expert and chief medical officer of Cero Therapeutics in California. 

“Some patients also experience bone pain or night sweats,” he told Fox News Digital.

Known risk factors for AML include prior chemotherapy or radiation, smoking, long-term benzene exposure and certain inherited syndromes, although most cases occur without any identifiable cause, according to Sikorski, who has not treated Schlossberg.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

In some rare cases, people can inherit mutations that cause AML to run in families, with recent research suggesting that these cases may be more common than previously thought, Chung noted.

“We used to only check for this in younger AML patients, but we now believe all patients should be screened for these mutations,” he said.

Treatment for AML

The standard treatment for AML is intensive chemotherapy with a combination of two drugs, with additional agents added based on each patient’s specific characteristics, according to Becker.

“We now believe all patients should be screened for these mutations.”

For patients with higher-risk types of AML, the chemotherapy is usually followed by a stem cell (bone marrow) transplant to prevent relapse. The transplants come from matched donors, often family members.

“This is a much more involved process that usually involves another month in the hospital, followed by close follow-up for many months, as well as a much higher risk for treatment-related side effects,” Chung said.

There is not a specific treatment that is effective for Schlossberg’s specific chromosome abnormality, the doctors noted, although some new cellular therapies and immunotherapies are being investigated.

For older patients who are not strong enough to receive intensive chemotherapy, the standard treatment is venetoclax/azacytidine (a combination therapy used to treat certain types of AML), Chung said.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“This can often be given mostly outside the hospital on a monthly basis,” he said. “While it technically is not considered to be curative, it can work very well — in some cases, patients remain in remission for many months, if not years.”

Hope ahead

There is hope on the horizon, as AML treatment has advanced more in the past decade than in the previous 30 years, according to Sikorski.

“New targeted drugs have been approved in several AML subtypes, and early work in immune-based therapies, including CAR-T and other engineered cell therapies, is beginning to reach clinical trials for AML,” Sikorski, told Fox News Digital.

CLICK HERE FOR MORE HEALTH STORIES

“Supportive care has also improved significantly, which helps patients tolerate treatment more effectively.” 

While there is not yet a drug tailored specifically to inversion 3, he reiterated, “many studies focused on high-risk AML are actively enrolling these patients, and the overall treatment landscape continues to expand.”

An experimental medication was shown to help boost weight loss by up to 20%, a study found.

Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes, according to a press release.

The drug was generally well-tolerated by the study participants.

The Phase 2 trial, which was funded by Eli Lilly, included 263 adults. After 48 weeks, they had lost between 9.5% and 20.1% of their body weight, compared to 0.4% for those taking the placebo.

Treatment with eloralintide was also linked to improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation, all of which can increase cardiometabolic risk, according to the researchers.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT

“The weight loss we saw in the study is clinically impactful,” lead study author Liana K. Billings, M.D., director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Skokie, Illinois, said in the press release. 

“With this degree of weight loss in only 48 weeks, we see people having improvement or resolution in other conditions like hypertension, hyperlipidemia, osteoarthritis, sleep apnea and more weight-related conditions.”

“Furthermore, in the study, we did not see a nadir or plateau of weight loss, so I would expect weight loss to continue if the study continued for a longer duration. Additionally, up to 90% of participants on eloralintide improved by at least one BMI category,” she added.

The results were published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, earlier this month.

AMERICA’S FATTEST STATES REVEALED — AND HOW OZEMPIC IS CHANGING THE MAP

While popular GLP-1 drugs — including Ozempic, Wegovy, Mounjaro and Zepbound — work by mimicking the gut hormone GLP-1 (glucagon-like peptide-1), eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin.

Similar to GLP-1s, it helps to slow digestion, reduce appetite and control blood sugar after meals. It has not yet been FDA-approved for clinical use.

The biggest side effects noted for eloralintide were mild to moderate gastrointestinal symptoms and fatigue, the researchers noted. These effects were greater at higher doses.

“Obesity is a complex condition, and no single treatment works for everyone,” said Billings.

“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them.”

COULD GLP-1 WEIGHT-LOSS MEDICATIONS LIKE OZEMPIC BECOME THE ‘EVERYTHING DRUG’?

Based on the trial results, the reseachers plan to launch Phase 3 clinical studies for obesity treatment by the end of this year, the president of Lilly Cardiometabolic Health confirmed to Fox News Digital. The drug is also being evaluated for use in combination with GLP-1 medications.

Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, shared some concerns about the new anti-obesity agents being developed.

“Between all the agents out there, there is no way any person cannot lose weight when coupled with progressive resistance training and attention to their daily macronutrient intake, even if only a little,” the doctor, who was not involved in the study, told Fox News Digital.

“Yet big pharma will continue to search for novel targets to introduce a new drug that will likely prove similarly, yet not more, efficacious than the current agents. There are enough agents out there to drive weight loss to a malnutrition status.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Osborn also noted that the lower cardiovascular risk associated with the drug was likely due to the participants losing body fat, which reduces the risk for all age-related diseases.

“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term.”

“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” he said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Sue Decotiis, M.D., a medical weight-loss doctor in New York City, also shared her thoughts on eloralintide’s potential as an alternative treatment.

“It seems that the more receptor systems that are influenced, the more weight a patient can lose,” she told Fox News Digital. “This is why tirzepatide (Mounjaro, Zepbound), which hits two receptors, induced more weight loss than Ozempic and Wegovy.”

“In my practice, I witnessed significantly better results with tirzepatide when patients were switched from Ozempic.”

Hitting more receptors may be the answer for those patients who do not respond well or who “hit the wall” with simpler drugs, according to Decotiis, who also was not involved in the study.

“For long-term safety and results, peptide drugs show promise,” she said.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Whitney Di Bona, in-house attorney and consumer safety advocate for Drugwatch, noted that while the Phase 2 results are “promising,” it is important to be cautious.

“These drugs have been used for years, but new safety concerns keep appearing,” the Florida-based expert told Fox News Digital. Some of those include a potentially serious eye condition, delayed stomach emptying, bowel obstruction and serious digestive problems, which have led to many lawsuits.

CLICK HERE FOR MORE HEALTH STORIES

“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term,” Di Bona advised. “Even with careful studies, some risks may only become clear after the drug is used by many people.”